Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 121

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 121
---
 |     | $                                                            | 35,000,000 |
| $                      |   10.00 |     |                                                 |  3,500,000 |     |                                            | 84.0% |     | $                                                            | 35,000,000 |
| $                      |   15.00 |     |                                                 |  2,333,333 |     |                                            | 77.7% |     | $                                                            | 34,999,995 |

__________________

| (1) | The purchase price assumes a discount to the market price of our shares, in accordance with the terms 
 of the Purchase Agreement.                                                                            |

| 60 |

| (2) | The denominator is based on 6,685,918,922 Ordinary Shares outstanding as of January 15, 2025, adjusted                                          
 to include the issuance of the number of Purchase Shares set forth in the adjacent column which we would have issued to the Selling Shareholder 
 based on the applicable assumed purchase price per share.                                                                                       |

| (3) | We will not receive any proceeds from the issuance of any Commitment Shares if issued to the Selling Shareholder                       
 to release the Company of its liability to pay the Commitment Fee. The proceeds reflected in this column would be reduced by an amount 
 equal to the product of the final Commitment Shares multiplied by the assumed purchase price per Depositary Share.                     |

| (4) | Represents the last reported sales price of our Depositary Shares on January 16, 2024, as reported by 
 NASDAQ, less a 5% discount.                                                                           |

| 61 |

<div align='center'>USE OF PROCEEDS</div>

We will not receive any of
the proceeds from the sale of Depositary Shares offered by the Selling Shareholder. In addition, we will not receive any proceeds from
the issuance or sale of the Commitment Shares if issued to the Selling Shareholder to release the Company of its liability to pay the
Commitment Fee. We may receive up to $35.0 million in aggregate gross proceeds from the Selling Shareholder under the Purchase Agreement
in connection with sales of our Depositary Shares to the Selling Shareholder pursuant to the Purchase Agreement after the date of this
prospectus. However, the actual proceeds may be less than this amount depending on the number of Depositary Shares sold and the price
at which the Depositary Shares are sold.

We intend to use any net proceeds
that we receive under the